 - LSD as a Treatment for Anxiety Disorders: New Evidence of Efficacy will present the most recent and robust data on LSD in patients with anxiety - - This study builds on decades of research on the effects of LSD in humans - NEW YORK , April 14, 2022 PRNewswire -- Mind Medicine MindMed Inc. NASDAQ: MNMD, NEO: MMED, the Company or MindMed, a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that Dr. Frederike Holze and Prof. Dr. Matthias Liechti, MindMed collaborators at University Hospital Basel UHB, will present results from the LSD-Assist Study, a Phase 2 investigator-initiated clinical trial of LSD in the treatment of anxiety disorders, at Londons PSYCH Symposium on May 11, 2022. 